Fig. 8

A 75-year-old woman with a low-differentiated primary cardiac sarcoma with microsatellite instability, treated with pembrolizumab (anti-PD-1). Baseline contrast-enhanced MRI image shows a large retroatrial mass (arrow). Two months follow-up (FU) imaging shows a good reduction in the size of the mass assessed as -34% according to iRECIST criteria (partial response, arrow). One year FU imaging shows a complete response